Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice.
Forty-five years ago a naturally attenuated tick-borne flavivirus, Langat (LGT) strain TP21, was recovered from ticks in Malaysia. Subsequently, it was tested as a live attenuated vaccine for virulent tick-borne encephalitis viruses. In a large clinical trial its attenuation was confirmed but there was evidence of a low level of residual virulence. Thirty-five years ago further attenuation of LGT TP21 was achieved by multiple passages in eggs to yield mutant E5. To study the genetic determinants of the further attenuation exhibited by E5 and to allow us to manipulate the genome of this virus for the purpose of developing a satisfactory live attenuated tick-borne flavivirus vaccine, we recovered infectious E5 virus from a full-length cDNA clone. The recombinant E5 virus (clone 651) recovered from a full-length infectious cDNA clone was more attenuated in immunodeficient mice than that of its biologically derived E5 parent. Increase in attenuation was associated with three amino acid substitutions, two located in the structural protein E and one in nonstructural protein NS4B. Subsequently an even greater degree of attenuation was achieved by creating a viable 320 nucleotide deletion in the 3'-noncoding region of infectious full-length E5 cDNA. This deletion mutant was not cytopathic in simian Vero cells and it replicated to lower titer than its E5-651 parent. In addition, the E5 3' deletion mutant was less neuroinvasive in SCID mice than its E5-651 parent. Significantly, the deletion mutant proved to be 119,750 times less neuroinvasive in SCID mice than its progenitor, LGT strain TP21. Despite its high level of attenuation, the E5 3' deletion mutant remained highly immunogenic and intraperitoneal (ip) inoculation of 10 PFU induced complete protection in Swiss mice against subsequent challenge with 2000 ip LD50 of the wild-type LGT TP21.
Pletnev
A G
AG
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA. apletnev@niaid.nih.gov
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D001483:Base Sequence; D001921:Brain / Q000473:pathology / Q000821:virology*; D002460:Cell Line; D002642:Chick Embryo; D002522:Chlorocebus aethiops; D003001:Cloning, Molecular; D016384:Consensus Sequence / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics; D004274:DNA, Recombinant / Q000235:genetics*; D004279:DNA, Viral / Q000235:genetics*; D004669:Encephalitis Viruses, Tick-Borne / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity*; D004675:Encephalitis, Tick-Borne / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000821:virology; D051379:Mice; D016513:Mice, SCID; D009500:Neutralization Tests; D010063:Ovum; D017384:Sequence Deletion / Q000235:genetics*; D012692:Serial Passage; D015996:Survival Rate; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology; D014774:Virulence / Q000235:genetics
D000914:Antibodies, Viral; D018076:DNA, Complementary; D004274:DNA, Recombinant; D004279:DNA, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines